Nalorex 50mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nalorex 50mg tablets

bristol-myers squibb pharmaceuticals ltd - naltrexone hydrochloride - oral tablet - 50mg

Azactam 1g powder for solution for injection vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

azactam 1g powder for solution for injection vials

bristol-myers squibb pharmaceuticals ltd - aztreonam - powder for solution for injection - 1gram

Azactam 2g powder for solution for injection vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

azactam 2g powder for solution for injection vials

bristol-myers squibb pharmaceuticals ltd - aztreonam - powder for solution for injection - 2gram

Perfalgan 1g/100ml solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

perfalgan 1g/100ml solution for infusion vials

bristol-myers squibb pharmaceuticals ltd - paracetamol - solution for infusion - 10mg/1ml

Yervoy New Zealand - English - Medsafe (Medicines Safety Authority)

yervoy

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.